Andrew Wang, M.D., Professor and Vice Chair for Translational Research and Commercialization in the Department of Radiation Oncology, is among 43 exemplary physicians, physicists, and cancer biologists selected as 2025 Fellows of the American Society for Radiation Oncology (ASTRO), the world’s largest professional organization in radiation oncology.

First awarded in 2006, the FASTRO designation honors ASTRO members who have made significant contributions to the Society and the field through research, education, patient care, and service. Of ASTRO’s 10,000 members worldwide, only 541 have received this distinction. Dr. Wang will be recognized Sept. 30 at ASTRO’s 67th Annual Meeting in San Francisco.

“It is a great honor. As a radiation oncologist, this is one of the greatest recognitions for my work and service to the Society,” said Dr. Wang, also a member of UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center.

Candidates for Fellow designation are nominated by current ASTRO Fellows, undergo rigorous peer review, and are approved by the Society’s Board of Directors. Dr. Wang’s nominators include Robert Timmerman, M.D., Chair and Professor of Radiation Oncology. He also shares the FASTRO distinction with another UTSW colleague, David Sher, M.D., M.P.H., Professor of Radiation Oncology and Chief of the Head and Neck Radiation Oncology Service, who was inducted as a Fellow last year.

“Dr. Andrew Wang is a highly influential, innovative, and successful radiation oncologist,” Dr. Timmerman wrote in his nomination letter. “He has supported the goals of ASTRO by being a highly accomplished researcher, bringing new understanding and treatment ultimately to the hands of all radiation oncologists. In addition, ASTRO has greatly benefited from his leadership and stewardship. … He is a dedicated clinician and teacher, admired and respected by his colleagues and students.”

Dr. Wang specializes in the clinical treatment of genitourinary and gastrointestinal cancers, and his research program aims to apply advances in engineering sciences to medicine. Continuously funded by the National Institutes of Health and Department of Defense since 2013, his research is at the intersection of nanomedicine, cancer immunology, and clinical oncology. His work is innovative and impactful, resulting in more than 40 patent applications.

Dr. Wang’s research is focused on the application of biomedical engineering to disease treatment. He pioneered the use of nanotherapeutics with radiation therapy to improve treatment outcomes. In addition, he has invented several novel cancer therapeutics, including an antigen-capturing nanoparticle that, when used in conjunction with radiation, can improve immunotherapy responses in cancer.

After earning his medical degree from Harvard Medical School, Dr. Wang completed an internship in internal medicine at St. Luke’s-Roosevelt Hospital Center in New York, a residency in radiation oncology at Harvard/Brigham and Women’s Hospital, and a postdoctoral fellowship at Massachusetts Institute of Technology. Following his tenure at the University of North Carolina, he joined the UTSW faculty in 2021.

Dr. Wang is also a Fellow of the American Association for the Advancement of Science (AAAS) and the American Institute for Medical and Biological Engineering (AIMBE), as well as a member of the American Society for Clinical Investigation (ASCI).